...Therapeutics Inc. Voyager Therapeutics Inc. Dopa decarboxylase (DDC) (AADC) GATA binding protein 4 (GATA4) Microtubule-associated protein tau (tau) (MAPT) (FTDP-17) Myocyte enhancer factor 2C (Mef2c) Potassium...

...TECHNOLOGY: Tissue markers Tumor levels of phosphorylated MEF2C could help predict responses to chemotherapy in AML...
...to chemotherapy in AML. In 47 patients treated with chemotherapy, high tumor levels of S222-phosphorylated MEF2C...
...wild-type MEF2C expression. In a xenograft mouse model of AML, tumor-specific knock-in of a phosphorylation-deficient MEF2C...

...studies suggest NMDA receptor antagonists could help treat autism caused by MEF2C haploinsufficiency. In an MEF2C-haploinsufficient...
...autism. The generic NMDA antagonist memantine is marketed to treat Alzheimer's disease. TARGET/MARKER/PATHWAY: NMDA receptor; myocyte enhancer factor 2C (MEF2C)...

...A study published in Nature Communications identified myocyte enhancer factor 2C (MEF2C) mutations as a source of abnormal brain development...
...abnormal brain development and function and suggests an NMDA receptor antagonist could help treat autism. MEF2C...
...impaired neurogenesis and decreased total hippocampal neurons and dendritic complexity compared with normal MEF2C expression. MEF2C...

...cells. A single administration of a gene therapy delivering GATA binding protein 4 (GATA4) , myocyte enhancer factor 2C (Mef2c)...
...administered daily for two weeks following a single dose of a gene therapy delivering GATA4, Mef2c...
...with the same Wnt and TGF beta inhibitors combined with a gene therapy delivering GATA4, Mef2c...